However, propofol and midazolam are widely used for intravenous sedation in very ill patients. Midazolam and propofol are used under light sedation in order to evaluate the effects of different sedation strategies on the clinical outcomes for sepsis patients. In a retrospective cross-sectional study between June 2021 and June 2023, an ICU in Baghdad Medical City examined sepsis patients who required mechanical ventilation and compared the sedation of those who got midazolam and propofol to those who did not. The outcomes of the sequential organ failure assessment (SOFA), day one acute physiology and chronic health evaluation II (APACHE II), and emergency surgery were all recorded for the patients. The midazolam and propofol groups each had 73 and 78 patients, with a mean age of 50 years (SD, 15.4 years) for the midazolam group and 56 years (SD, 16 years) for the propofol group, respectively. Of these participants, 52 (71.2%) and 56 (71.8%) were men. Midazolam and propofol groups' median APACHE II scores were 21 (17-25) and 20(16-25), respectively. The median SOFA scores for midazolam and propofol were 6(4-8) and 6(4-9) respectively. In comparison to propofol groups, midazolam groups had longer median weaning periods, recovery times, and lengths of stays. Both the midazolam and propofol groups had higher rates of infection in the belly, lungs, and other body regions; the length of artificial breathing in both the midazolam and propofol groups exceeded 5 days. To support this finding, additional prospective studies are required.
Published Date: 2023-10-30; Received Date: 2023-10-05
